Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The original Celgene-Anokion alliance ($45M upfront, up to $10M preclinical milestones, equity stake, acquisition option) targeted antigen-specific tolerance…
After four years of preclinical work, Anokion is bringing one of the more promising celiac candidates (KAN-101) toward the clinic with $40M Series B and an…
We are excited to expand our relationship with Bristol Myers Squibb, which underscores the substantial therapeutic opportunity we believe our programs hold for…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS and Anokion/Kanyos established a strategic collaboration on antigen-specific tolerance therapeutics for autoimmune diseases including MS, type 1 diabetes and celiac disease. BMS made an upfront equity investment plus committed to option exercise payments and milestones up to ~$1.3B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Anokion SA / Kanyos Bio Inc. (this deal) | 2019 | $1.3B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2019 deals · Bristol-Myers Squibb Company deals · Metabolic deals